Allarity Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.92next fiscal year
Monitoring Framework
Key Performance Indicators
Stenoparib Phase 2 Trial Enrollment (NCT03878849) QuarterlyTarget: Complete enrollment of platinum-resistant or platinum-ineligible ovarian cancer patients
Cash and Restricted Cash Balance Quarterly29.8MTarget: Maintain sufficient runway to fund operations for at least 12 months
Stenoparib API Manufacturing Campaign Completion QuarterlyTarget: Completion in Q3 2026
Watch Items
- Stenoparib combination trial with temozolomide in relapsed small cell lung cancer (SCLC)Trigger: Enrollment progress across multiple VA sites in the USAction: Monitor clinical updates and initial safety/efficacy signals
- Issuance of allowed U.S. patent for stenoparib-specific DRP companion diagnosticTrigger: Official patent issuance by the USPTOAction: Confirm extension of exclusivity horizon by at least 11 years
- Monthly redemptions under Streeterville Capital promissory notesTrigger: Lender requiring monthly redemptions up to $250,000 starting 6 months post-issuance (September 2026)Action: Assess impact on cash runway and liquidity
Research as of 20 Jun 2026